Prophase labs announces formation of clinical science advisory board to accelerate commercialization of be-smarttm esophageal disease diagnostic platform

Uniondale, ny, june 06, 2025 (globe newswire) -- prophase labs inc. (nasdaq: prph), (the “company” or “prophase”) a next generation biotech, genomics and consumer products company, today announced the formation of its clinical science advisory board to support the clinical adoption and commercialization of its breakthrough be-smarttm molecular test for esophageal disease. the advisory board will provide expert strategic guidance as prophase leads the regulatory and commercialization pathway for be-smart, with the goal of establishing a new clinical and economic standard in the early detection and management of esophageal cancer risk.
PRPH Ratings Summary
PRPH Quant Ranking